- Home
- DMAC vs SCPH Comparison
DMAC vs SCPH Comparison
Compare DMAC & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- SCPH
- Stock Information
- Founded
- DMAC 2000
- SCPH 2013
- Country
- DMAC United States
- SCPH United States
- Employees
- DMAC N/A
- SCPH N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- DMAC Health Care
- SCPH Health Care
- Exchange
- DMAC Nasdaq
- SCPH Nasdaq
- Market Cap
- DMAC 260.0M
- SCPH 173.6M
- IPO Year
- DMAC N/A
- SCPH 2017
- Fundamental
- Price
- DMAC $4.45
- SCPH $5.25
- Analyst Decision
- DMAC Strong Buy
- SCPH Strong Buy
- Analyst Count
- DMAC 4
- SCPH 3
- Target Price
- DMAC $10.75
- SCPH $14.00
- AVG Volume (30 Days)
- DMAC 393.5K
- SCPH 315.0K
- Earning Date
- DMAC 08-06-2025
- SCPH 08-13-2025
- Dividend Yield
- DMAC N/A
- SCPH N/A
- EPS Growth
- DMAC N/A
- SCPH N/A
- EPS
- DMAC N/A
- SCPH N/A
- Revenue
- DMAC N/A
- SCPH $41,982,000.00
- Revenue This Year
- DMAC N/A
- SCPH $108.95
- Revenue Next Year
- DMAC N/A
- SCPH $73.83
- P/E Ratio
- DMAC N/A
- SCPH N/A
- Revenue Growth
- DMAC N/A
- SCPH 138.10
- 52 Week Low
- DMAC $3.19
- SCPH $1.94
- 52 Week High
- DMAC $6.82
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- DMAC 53.15
- SCPH 63.11
- Support Level
- DMAC $4.81
- SCPH $5.37
- Resistance Level
- DMAC $5.60
- SCPH $6.28
- Average True Range (ATR)
- DMAC 0.49
- SCPH 0.31
- MACD
- DMAC 0.05
- SCPH 0.04
- Stochastic Oscillator
- DMAC 43.21
- SCPH 47.72
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.